A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
Clinical trial NCT07017725 · RECRUITING
Trial details
- NCT number
- NCT07017725
- Sponsor
- CASI pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-03
- Primary completion
- 2026-06-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.